Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor -Pipeline Insight, 2020

June 2020 | 120 pages | ID: P662EF934B1EN
DelveInsight

Abstracts

This report can be delivered to the clients within 48 hours

OVERVIEW

'Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor - Pipeline Insight, 2020' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor pipeline landscape is provided, which includes the topic overview and Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor mechanism of action. The assessment part of the report embraces, in-depth Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes the product description, mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor pipeline development activities

The report provides insights into:

• All the companies developing therapies of Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor with aggregate therapies developed by each company for the same.
• Different therapeutic candidates in early-stage, mid-stage and late stage of development for Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor.
• Key players involved in Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Collaborations (company-company collaborations and company-academia collaborations), licensing agreements and financing details for future developments of Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third party sources, etc.
Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Analytical Perspective by DelveInsight

• In-depth Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Commercial Assessment of products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, acquisition deal value trends. The sub-segmentation is described in the report, which provides company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form.

• Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this mechanism of action.

SCOPE OF THE REPORT

• The Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA the complete product development cycle, including all clinical and nonclinical stages.
• It comprises of detailed profiles of Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor therapeutic products with key coverage of involved technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.
• Elucidated Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor research and development progress and trial details, results wherever available, are also included in the pipeline study.
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor.

REPORT HIGHLIGHTS

• In the coming years, the Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor market is set to change due to the extensive research in this filed, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• There are several companies involved in developing therapies for Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor. Launch of emerging therapies of Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor will significantly impact the market.
• A better understanding of the target mechanism will also contribute to the development of novel therapeutics for Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

KEY QUESTIONS

• What are the current treatment options available based on the Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor?
• How many companies are developing therapies by working on Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor?
• What are the principal therapies developed by these companies in the industry?
• How many therapies are developed by each company for Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor to treat disease condition?
• How many emerging therapies are in early-stage, mid-stage, and late stage of development for Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor?
• Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other treatments?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor therapies?
• Which are the dormant and discontinued products and the reasons for the same?
• What is the unmet need for current therapies developed based on this mechanism of action?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor and their status?
• What are the results of the clinical studies and their safety and efficacy?
• What are the key designations that have been granted for the emerging therapies for Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor?
• How many patents are granted and pending for the emerging therapies of Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor?

Contents

1. REPORT INTRODUCTION

2. POLY (ADP-RIBOSE) POLYMERASE 1 (PARP) INHIBITOR

2.1. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Overview
2.2. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Classification
2.3. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Structure
2.4. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Mechanism of Action
2.5. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Application

3. POLY (ADP-RIBOSE) POLYMERASE 1 (PARP) INHIBITOR - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

3.1. In-depth Commercial Assessment
  3.1.1. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor companies collaborations, Licensing, Acquisition Deal Value Trends
    3.1.1.1. Assessment Summary
  3.1.2. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Collaboration Deals
    3.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis
    3.1.2.2. Company-University Collaborations (Licensing/Partnering) Analysis
    3.1.2.3. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Acquisition Analysis

4. THERAPEUTIC ASSESSMENT

4.1. Clinical Assessment of Pipeline Drugs
  4.1.1. Assessment by Phase of Development
  4.1.2. Assessment by Product Type (Mono/Combination)
    4.1.2.1. Assessment by Stage and Product Type
  4.1.3. Assessment by Route of Administration
    4.1.3.1. Assessment by Stage and Route of Administration
  4.1.4. Assessment by Molecule Type
    4.1.4.1. Assessment by Stage and Molecule Type
  4.1.5. Assessment by MOA
    4.1.5.1. Assessment by Stage and MOA
  4.1.6. Assessment by Target
    4.1.6.1. Assessment by Stage and Target

5. LATE STAGE PRODUCTS (PHASE-III)

6. MID STAGE PRODUCTS (PHASE-II)

7. EARLY STAGE PRODUCTS (PHASE-I)

8. PRE-CLINICAL PRODUCTS AND DISCOVERY STAGE PRODUCTS

9. INACTIVE PRODUCTS

10. DORMANT PRODUCTS

11. DISCONTINUED PRODUCTS

12. POLY (ADP-RIBOSE) POLYMERASE 1 (PARP) INHIBITOR PRODUCT PROFILES

12.1. Drug Name: Company
  12.1.1. Product Description
    12.1.1.1. Product Overview
    12.1.1.2. Mechanism of action
  12.1.2. Research and Development
    12.1.2.1. Clinical Studies
  12.1.3. Product Development Activities
    12.1.3.1. Collaboration
    12.1.3.2. Agreements
    12.1.3.3. Acquisition
    12.1.3.4. Patent Detail
  12.1.4. Tabulated Product Summary
    12.1.4.1. General Description Table
Detailed information in the report

13. POLY (ADP-RIBOSE) POLYMERASE 1 (PARP) INHIBITOR KEY COMPANIES

14. POLY (ADP-RIBOSE) POLYMERASE 1 (PARP) INHIBITOR KEY PRODUCTS

15. DORMANT AND DISCONTINUED PRODUCTS

15.1. Dormant Products
  15.1.1. Reasons for being dormant
15.2. Discontinued Products
  15.2.1. Reasons for the discontinuation

16. POLY (ADP-RIBOSE) POLYMERASE 1 (PARP) INHIBITOR - UNMET NEEDS

17. POLY (ADP-RIBOSE) POLYMERASE 1 (PARP) INHIBITOR - FUTURE PERSPECTIVES

18. POLY (ADP-RIBOSE) POLYMERASE 1 (PARP) INHIBITOR ANALYST REVIEW

19. APPENDIX

20. REPORT METHODOLOGY

20.1. Secondary Research
20.2. Expert Panel Validation

List Of Tables

LIST OF TABLES

Table 1 : Assessment Summary
Table 2 : Company-Company Collaborations (Licensing/Partnering) Analysis
Table 3 : Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Acquisition Analysis
Table 4 : Assessment by Phase of Development
Table 5 : Assessment by Product Type (Mono/Combination)
Table 6 : Assessment by Stage and Product Type
Table 7 : Assessment by Route of Administration
Table 8 : Assessment by Stage and Route of Administration
Table 9 : Assessment by Molecule Type
Table 10 : Assessment by Stage and Molecule Type
Table 11 : Assessment by MOA
Table 12 : Assessment by Stage and MOA
Table 13 : Assessment by Target
Table 14 : Assessment by Stage and Target
Table 15 : Late Stage Products (Phase-III)
Table 16 : Mid Stage Products (Phase-II)
Table 17 : Early Stage Products (Phase-I)
Table 18 : Pre-clinical and Discovery Stage Products
Table 19 : Inactive Products
Table 20 : Dormant Products
Table 21 : Discontinued Products

List Of Figures

LIST OF FIGURES

Figure 1 : Structure
Figure 2 : Mechanism
Figure 3 : Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor companies collaborations, Licensing, Acquisition Deal Value Trends
Figure 4 : Company-Company Collaborations (Licensing/Partnering) Analysis
Figure 5 : Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Acquisition Analysis
Figure 6 : Assessment by Phase of Development
Figure 7 : Assessment by Product Type (Mono/Combination)
Figure 8 : Assessment by Stage and Product Type
Figure 9 : Assessment by Route of Administration
Figure 10 : Assessment by Stage and Route of Administration
Figure 11 : Assessment by Molecule Type
Figure 12 : Assessment by Stage and Molecule Type
Figure 13 : Assessment by MOA
Figure 14 : Assessment by Stage and MOA
Figure 15 : Late Stage Products (Phase-III)
Figure 16 : Mid Stage Products (Phase-II)
Figure 17 : Early Stage Products (Phase-I)
Figure 18 : Pre-clinical and Discovery Stage Products
Figure 19 : Inactive Products
Figure 20 : Dormant Products
Figure 21 : Discontinued Products
Figure 22 : Unmet Needs

KEY COMPANIES

Abbvie
Pfizer
Esai
Esai
Esai
Mitsubishi Tanabe Pharma Corporation
AbbVie
Jiangxi Qingfeng Pharmaceutical
Zydus Cadila
Jeil Pharmaceutical
Jeil Pharmaceutical
Angion Biomedica
Sanofi
NewGen Therapeutics
Kanion
& list continues